Articles, announcements and insights from Horizon Discovery

Is CRAF required for the maintenance of KRAS mutant non-small cell lung cancer?

Jun 10, 2016 12:57:49 PM No Comments

KRAS is one of the most frequently mutated genes in cancer, but targeting KRAS with potent small molecules has proved to be difficult. Moreover, although inhibitors of BRAF and MEK, which are downstream targets of KRAS, have been developed, they have transient benefits only in patients with melanoma who have mutated BRAF. Therefore, an effective therapy for KRAS-driven tumours remains a pressing unmet medical need.

Read More Gene editing, Target identification, Target validation

Using CRISPR for target identification and target validation

Jun 10, 2016 12:51:33 PM No Comments

The discovery of the CRISPR‐Cas system in bacteria has initiated an impressive array of innovations that have enabled the use of the RNA‐guided Cas9 nuclease in functional genomic screens. At Horizon, we have embraced these developments, as they provide new opportunities for drug target identification and validation. The case studies presented in this below highlight how we use this technology to successfully conduct genome wide and focused sgRNA library screens and to verify whether specific genes are required for the survival and/or proliferation of cancer cell lines.

Read More Target identification, Target validation, CRISPR Screening

Subscribe to Email Updates

RECENT POSTS